Actively Recruiting
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Led by Kelonia Therapeutics, Inc. · Updated on 2026-04-24
70
Participants Needed
7
Research Sites
876 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
CONDITIONS
Official Title
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have relapsed and refractory multiple myeloma with measurable disease
- Participants must have received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory drug, and a CD38-directed monoclonal antibody
- Participants must have an Eastern Cooperative Group (ECOG) performance status of 0-1
- Participants must have acceptable laboratory values as defined by the protocol
You will not qualify if you...
- Participants must not have known central nervous system involvement with myeloma
- Participants cannot have plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or primary light chain amyloidosis
- Participants cannot have ongoing acute systemic infection requiring antimicrobial therapy
- Participants cannot require systemic steroids for any condition
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
City of Hope
Duarte, California, United States, 91010
Actively Recruiting
2
Stanford University
Palo Alto, California, United States, 94304
Actively Recruiting
3
Emory University Hospital
Atlanta, Georgia, United States, 30322
Actively Recruiting
4
Providence Portland Medical Center
Portland, Oregon, United States, 97213
Actively Recruiting
5
The Royal Prince Alfred
Camperdown, New South Wales, Australia, 2050
Actively Recruiting
6
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia, 3000
Actively Recruiting
7
The Alfred Paula Fox Melanoma and Cancer Centre
Melbourne, Victoria, Australia, 3004
Actively Recruiting
Research Team
S
SVP Clinical Development
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here